Effects of azilsartan in chronik kidney disease with hypertension

Effects of azilsartan in chronik kidney disease with hypertension - Azilsartan in chronic kidney disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010788

Enrollment

Registered

2013-05-23

Start date

2013-05-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronick kidney disease with hypertension

Interventions

azilsartan 20-40mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) >=20 years old 2)chronic kidney disease at stage G1-5 that are treated with angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) 3)hypertension(140/90 mmHg) irrespected of antihypertensive therapy

Exclusion criteria

Exclusion criteria: 1)acute kindey injury 2)severe heart failure 3)type I or type II diabetes mellitus with poor glucose control (serum glycosylated hemoglobin [HbA1c] level > 9%) 4)severe liver dysfunction 5)hyperkalemia (> 5.5 mEq/ml) 6)pregnant women 7)patinets who will not give informed concent 8)patinets who have allegry for azilsartan

Design outcomes

Primary

Measure	Time frame
The change of blood pressure, heart function, renal function	—

Countries

Japan

Contacts

Public ContactYoshiyuki Morishita

Jichi Medical University Division of Nephrology, Department of Internal medicine

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026